FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) ...

Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...

NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...

Lupin’s ANDA received tentative FDA approval for four enzalutamide tablet strengths, with final approval deferred until ...

Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) ...

The US FDA has issued a complete response letter (CRL) for gallium Ga 68 edotreotide (LNTH-2501), a positron emission tomography (PET) diagnostic kit developed by Lantheus Holdings for localizing ...

Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...

Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk ...

Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding ...